Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Change in Accured Expenses (2018 - 2025)

Historic Change in Accured Expenses for Revolution Medicines (RVMD) over the last 8 years, with Q3 2025 value amounting to $45.3 million.

  • Revolution Medicines' Change in Accured Expenses rose 34056.03% to $45.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.0 million, marking a year-over-year increase of 301708.91%. This contributed to the annual value of $22.0 million for FY2024, which is 4988.41% up from last year.
  • Revolution Medicines' Change in Accured Expenses amounted to $45.3 million in Q3 2025, which was up 34056.03% from $10.8 million recorded in Q2 2025.
  • In the past 5 years, Revolution Medicines' Change in Accured Expenses registered a high of $45.3 million during Q3 2025, and its lowest value of -$21.3 million during Q1 2024.
  • For the 5-year period, Revolution Medicines' Change in Accured Expenses averaged around $5.5 million, with its median value being $2.0 million (2021).
  • Its Change in Accured Expenses has fluctuated over the past 5 years, first surged by 205968.59% in 2021, then crashed by 111341.32% in 2024.
  • Revolution Medicines' Change in Accured Expenses (Quarter) stood at $3.7 million in 2021, then plummeted by 179.24% to -$3.0 million in 2022, then crashed by 112.1% to -$6.3 million in 2023, then soared by 390.86% to $18.3 million in 2024, then skyrocketed by 147.54% to $45.3 million in 2025.
  • Its Change in Accured Expenses was $45.3 million in Q3 2025, compared to $10.8 million in Q2 2025 and $1.5 million in Q1 2025.